Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

First Albany Keeps Buy on Gilead Sciences

First Albany reiterated its buy rating on Gilead Sciences (GILD).

Analyst David Webber says he's reiterating his buy rating following the release of preliminary data on Gilead's Viread/Emtriva drug combination against GlaxoSmithKline's Combivir in a study of HIV patients. He notes Gilead reported, among other things, that a statistically significant greater number of patients achieved a pre-set goal for reduced levels of the HIV virus with Gilead drugs vs. Combivir.

Webber says the early study data suggest Gilead's newly approved Viread/Emtriva drug combination, Truvada, will compare favorably to Combivir in final study results and facilitate market share gain at the expense of Combivir. He keeps the $76 target.

blog comments powered by Disqus